A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

July 4, 2012

Primary Completion Date

July 22, 2016

Study Completion Date

October 31, 2018

Conditions
Multiple Myeloma
Interventions
DRUG

Carfilzomib

Carfilzomib was administered as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day treatment cycle.

DRUG

Dexamethasone

Dexamethasone was administered at a dose of 40 mg IV or orally (PO) on days 1, 8, 15, and 22 for the first 8 cycles; starting with cycle 9 dexamethasone was administered on days 1, 8, and 15.

Trial Locations (35)

Unknown

Arizona Oncology Associates, Tucson

Comprehensive Blood and Cancer Center (CCBC), Bakersfield

California Cancer Associates for Research and Excellence, Encinitas

Robert A. Moss, M.D., FACP, Inc., Fountain Valley

California Cancer Associates for Research and Excellence, Fresno

Cedars-Sinai Medical Center, Los Angeles

Monterey Bay Oncology, Salinas

Sansum Clinic, Santa Barbara

Central Coast Medical Oncology Corporation, Santa Maria

James R. Berenson M.D. Inc., West Hollywood

The Oncology Insititute of Hope and Innovation, Whittier

Rocky Mountain Cancer Centers, Denver

Florida Cancer Specialists - South, Fort Myers

Florida Cancer Specialists - North, Tampa

Illinois Cancer Care, Galesburg

Illinois Cancer Specialists, Hinsdale

Illinois Cancer Specialists, Niles

Fort Wayne Oncology & Hematology, Fort Wayne

Horizon Oncology Research, Inc., Lafayette

Center for Cancer and Blood Disorders (CCBD), Bethesda

Hematology-Oncology Associates of Northern NJ, PA, Morristown

New Mexico Cancer Care Alliance, Albuquerque

Clinical Research Alliance, New York

Hudson Valley Hematology Oncology Associates, Poughkeepsie

Willamette Valley Cancer Institute and Research Center, Eugene

Tennessee Oncology, PLLC, Chattanooga

St. Joseph Regional Cancer Center, Bryan

Millennium Oncology, Houston

Waldron Medical Research and Development Center, Houston

Cancer Care Centers of South Texas, San Antonio

Center at Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio, San Antonio

Blood and Cancer Center of East Texas, Tyler

Shenandoah Oncology, PC, Winchester

Northwest Cancer Specialists, Vancouver

Yakima Valley Memorial Hospital/ North Star Lodge, Yakima

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01677858 - A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma | Biotech Hunter | Biotech Hunter